by MM360 Staff | Jun 10, 2021 | Twitter
@SurbhiSidanaMD #ASCO21 What about non-BCMA novel therapies? #mmsm pic.twitter.com/HUAWHWjzSY— Multiple Myeloma Hub (@MM_Hub) June 8, 2021
by MM360 Staff | Jun 10, 2021 | Twitter
Big thank you 🙌 to @SurbhiSidanaMD for summarizing and putting into perspective the exciting new data presented at #ASCO21 on #CARTcells and T-cell engagers for relapsed #myeloma #mmsm pic.twitter.com/f5oNHeeTLM— Multiple Myeloma Hub (@MM_Hub) June 8, 2021
by MM360 Staff | Jun 10, 2021 | Twitter
CONGRESS | #ASCO21 | @BerdejaJesus presents the updated results of the MonumenTAL-1 trial, evaluating talquetamab, a novel bsAb targeting GPRC5D/CD3, in heavily pretreated patients with RRMM #mmsm @SarahCannonDocs pic.twitter.com/fFyXdM3tMq— Multiple Myeloma Hub...
by MM360 Staff | Jun 10, 2021 | Twitter
#ASCO21 Tuesday 8AM EST ➡️Plasma Cell Dyscrasia Session ➡️Please join me and my colleague @PLMcCarthyMD for fantastic presentations on #myeloma with @profBigG @Ccostello7 @szusmani @NBahlis @DoctorAKrishnan @BerdejaJesus @SurbhiSidanaMD https://t.co/Iny6YvtqUc—...
by MM360 Staff | Jun 10, 2021 | Twitter
Excellent presentation by Faith Davis @ASCO on HRMM➡️55% affected MM cells as cutoff to determine significance of del17➡️highest risk in patients with del17p and mutations 17p in remaining allel➡️functional HR if PFS is less than 18 mos #mmsm #ASCO21 #myeloma...
by MM360 Staff | Jun 10, 2021 | Twitter
My Top 5 myeloma abstracts at #ASCO21 https://t.co/8XiVRz451o— Vincent Rajkumar (@VincentRK) June 7, 2021
